SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-021187
Filing Date
2023-05-11
Accepted
2023-05-11 16:02:15
Documents
64
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q spro-20230331.htm   iXBRL 10-Q 2578281
2 EX-10.1 spro-ex10_1.htm EX-10.1 23756
3 EX-31.1 spro-ex31_1.htm EX-31.1 12767
4 EX-31.2 spro-ex31_2.htm EX-31.2 12790
5 EX-32 spro-ex32.htm EX-32 11579
  Complete submission text file 0000950170-23-021187.txt   8770332

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT spro-20230331_def.xml EX-101.DEF 234564
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT spro-20230331_pre.xml EX-101.PRE 389919
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT spro-20230331_cal.xml EX-101.CAL 41709
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT spro-20230331_lab.xml EX-101.LAB 505564
10 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT spro-20230331.xsd EX-101.SCH 72603
58 EXTRACTED XBRL INSTANCE DOCUMENT spro-20230331_htm.xml XML 1351849
Mailing Address 675 MASSACHUSETTS AVENUE 14TH FLOOR CAMBRIDGE MA 02139
Business Address 675 MASSACHUSETTS AVENUE 14TH FLOOR CAMBRIDGE MA 02139 857-242-1600
Spero Therapeutics, Inc. (Filer) CIK: 0001701108 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38266 | Film No.: 23910805
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences